Skip to main content
. 2023 Jul 28;32:100690. doi: 10.1016/j.lanepe.2023.100690

Fig. 4.

Fig. 4

Change in number of exacerbations. Change in total number of exacerbations in the year before and the year after initiation of elexacaftor/tezacaftor/ivacaftor (ETI) therapy (left panel) and change in exacerbation severity category in the year before vs. the year after initiation of ETI therapy (right panel). pwCF, people with cystic fibrosis.